Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

Exclusion Criteria19

• Availability of and patient acceptance of curative therapy
• Uncontrolled infection
• Active tuberculosis or hepatitis, or chronic hepatitis
• Any of the following prior therapies:
• Chemotherapy (IMIDs, alkylating agents, proteosome inhibitors) =\< 2 weeks prior to registration
• Immunotherapy (monoclonal antibodies) =\< 4 weeks prior to registration
• Experimental agent in case of Acute Myeloid Leukemia (AML) or TCL within 4 half-lives of the last dose of the agent
• New York Heart Association classification III or IV, known symptomatic coronary artery disease, or symptoms of coronary artery disease on systems review, or known cardiac arrhythmias \[atrial fibrillation or supraventricular tachycardia (SVT)\]
• Active CNS disorder or seizure disorder or known CNS disease or neurologic symptomatology; in case of AML active CNS involvement as detected by lumbar puncture or neuro-imaging (only to be done if clinically indicated)
• Human immunodeficiency virus (HIV) positive test result or other immunodeficiency or immunosuppression
• Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (used for a non-Food and Drug Administration \[FDA\] approved indication and in the context of a research investigation);
• NOTE: in TCL, patients may use topical emollients or corticosteroids, acetic acid soaks, etc. to control pruritis and prevent infection; no topical chemotherapy is allowed (no topical nitrogen mustard)
• Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown:
• Pregnant women or women of reproductive ability who are unwilling to use effective contraception
• Nursing women
• Men who are unwilling to use a condom (even if they have undergone a prior vasectomy) while having intercourse with any woman, while taking the drug and for 4 weeks after stopping treatment
• Diagnosis of AML
• Diagnosis of Angioimmunoblastic T-cell Lymphoma (AITL)
• Hypersensitivity to ipilimumab or its excipients